# Alamar Biosciences, Inc.: overview

ALMR · Nasdaq · CIK 2104204 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/almr.md) · [Financials](/companies/almr/financials.md) · [Filings](/companies/almr/filings.md) · [Insiders](/companies/almr/insiders.md)

Latest reported revenue: [$29.4m](/filings/0001193125-26-343003.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-343003).

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.1](/filings/0001193125-26-213424.md) | [16.2](/filings/0001193125-26-343003.md) | [26.0](/filings/0001193125-26-213424.md) | [29.4](/filings/0001193125-26-343003.md) |
| Gross margin | % | [48.8%](/filings/0001193125-26-213424.md) | [53.1%](/filings/0001193125-26-343003.md) | [55.5%](/filings/0001193125-26-213424.md) | [60.2%](/filings/0001193125-26-343003.md) |
| Operating margin | % | [(65.3%)](/filings/0001193125-26-213424.md) | [(49.0%)](/filings/0001193125-26-343003.md) | [(47.4%)](/filings/0001193125-26-213424.md) | [(46.0%)](/filings/0001193125-26-343003.md) |
| Net margin | % | [(58.5%)](/filings/0001193125-26-343003.md) | [(43.5%)](/filings/0001193125-26-343003.md) | [(81.9%)](/filings/0001193125-26-343003.md) | [(44.9%)](/filings/0001193125-26-343003.md) |
| Diluted EPS | $ per share | [(0.68)](/filings/0001193125-26-213424.md) | [(0.62)](/filings/0001193125-26-343003.md) | [(1.74)](/filings/0001193125-26-213424.md) | [(0.22)](/filings/0001193125-26-343003.md) |
| Free cash flow | $m | [(13.6)](/filings/0001193125-26-213424.md) | [(12.6) d](/filings/0001193125-26-343003.md) | [(20.9)](/filings/0001193125-26-213424.md) | [(15.0) d](/filings/0001193125-26-343003.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure.

## Last five fiscal years

Not reported.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/almr/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-28 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 8,450 | $33.11 | $279.8k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-28 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 9,846 | $32.47 | $319.7k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-28 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 7,058 | $33.11 | $233.7k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-28 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 8,224 | $32.47 | $267.0k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-28 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 30,249 | $33.11 | $1.0m | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-28 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 35,248 | $32.47 | $1.1m | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-28 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 814 | $33.11 | $27.0k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-28 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 948 | $32.47 | $30.8k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 4,226 | $31.88 | $134.7k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 9,791 | $31.33 | $306.8k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 1,386 | $30.33 | $42.0k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 3,531 | $31.88 | $112.6k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 8,178 | $31.33 | $256.2k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 1,157 | $30.33 | $35.1k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 15,131 | $31.88 | $482.4k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 35,049 | $31.33 | $1.1m | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 4,960 | $30.33 | $150.4k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 408 | $31.88 | $13.0k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 943 | $31.33 | $29.5k | [Form 4](/filings/0001231919-26-001508.md) |
| 2026-10-27 | [Qiming Corporate GP VI, Ltd.](/insiders/2059127.md) | 10% owner | Sale (S) | 134 | $30.33 | $4.1k | [Form 4](/filings/0001231919-26-001508.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Sands Capital Alternatives, LLC](/funds/1846444.md) | 2026-06-30 | $114.6m | 4,230,926 |  | New +4,230,926 |
| [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $67.2m | 2,480,310 |  | New +2,480,310 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $37.2m | 1,373,959 |  | New +1,373,959 |
| [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $29.4m | 1,083,983 |  | New +1,083,983 |
| [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $27.2m | 1,003,077 |  | New +1,003,077 |
| [HHLR ADVISORS, LTD.](/funds/1762304.md) | 2026-06-30 | $25.9m | 956,462 |  | New +956,462 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $24.7m | 911,445 |  | New +911,445 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $23.5m | 865,764 |  | New +865,764 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $22.5m | 829,424 |  | New +829,424 |
| [PURA VIDA INVESTMENTS, LLC](/funds/1590144.md) | 2026-06-30 | $20.5m | 755,909 |  | New +755,909 |

## Recent filings

[All 59 filings](/companies/almr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-01 | 16:01 ET | [8-K](/filings/0001193125-26-378360.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-378360 |
| 2026-08-11 | 20:30 ET | [10-Q](/filings/0001193125-26-343003.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343003 |
| 2026-08-10 | 16:10 ET | [8-K](/filings/0001193125-26-342378.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342378 |
| 2026-07-15 | 16:04 ET | [8-K](/filings/0001193125-26-304736.md) | 8.01 Other events | 0001193125-26-304736 |
| 2026-07-07 | 16:55 ET | [SCHEDULE 13D/A](/filings/0001875620-26-000010.md) | Ownership report, active investor, amended | 0001875620-26-000010 |
| 2026-05-08 | 08:30 ET | [10-Q](/filings/0001193125-26-213424.md) | Quarterly report, period 2026-03-31 | 0001193125-26-213424 |
| 2026-05-08 | 08:05 ET | [8-K](/filings/0001193125-26-213379.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-213379 |
| 2026-04-23 | 16:24 ET | [SCHEDULE 13D](/filings/0001193125-26-173780.md) | Ownership report, active investor | 0001193125-26-173780 |
| 2026-04-23 | 13:57 ET | [SCHEDULE 13D](/filings/0001875620-26-000007.md) | Ownership report, active investor | 0001875620-26-000007 |
| 2026-04-20 | 16:02 ET | [8-K](/filings/0001193125-26-163921.md) | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-163921 |

## Latest annual report

No annual report is in coverage.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c89a27b1-d6c6-4b7e-9fc7-a18faeb8f5ae)

## About the filer

- CIK: 2104204
- Tickers: ALMR
- Exchange: Nasdaq
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:10 ET. No prices; not investment advice.